Johnson & Johnson (Ethicon) Acquires Auris Health

Johnson & Johnson Completes Acquisition of Abiomed

December 22, 2022

Medical Devices

Johnson & Johnson completed its acquisition of Abiomed through a tender offer and subsequent merger, for an upfront payment of $380.00 per share in cash (enterprise value ~ $16.6 billion), plus a non-tradeable contingent value right (CVR) up to $35.00 per share based on milestones. Abiomed will operate as a standalone business within Johnson & Johnson’s MedTech segment.

Johnson & Johnson to Acquire Ambrx Biopharma in ~$2 Billion All-Cash Deal

January 8, 2024

Pharmaceuticals

Johnson & Johnson announced it has entered into a definitive agreement to acquire Ambrx Biopharma in an all-cash merger transaction valued at about $2 billion (about $1.9 billion net of estimated cash acquired). The deal is intended to add Ambrx’s proprietary synthetic biology and ADC (antibody-drug conjugate) technology platform and its clinical and preclinical oncology pipeline to J&J’s targeted oncology therapeutics efforts.

Alcon Acquires Majority Interest in Aurion Biotech, Inc.

March 26, 2025

Biotechnology

Alcon has acquired a majority interest in clinical-stage Aurion Biotech to accelerate development and commercialization of Aurion's allogeneic corneal cell therapy AURN001. Aurion will remain a separate company while leveraging Alcon's global R&D, regulatory and commercial capabilities to advance AURN001 into U.S. Phase 3 development in the second half of 2025.

Audax Private Equity Acquires Aspen Surgical Business Unit from Hillrom

July 10, 2019

Medical Devices

Audax Private Equity has entered into a definitive agreement to acquire Aspen Surgical, a Hillrom business unit that manufactures branded and private-label single-use surgical consumables. Aspen Surgical is headquartered in Caledonia, Michigan with operations in Caledonia and Las Piedras, Puerto Rico, and employs approximately 500 people; the transaction is a divestiture of the surgical consumables business from Hillrom to Audax.

Johnson & Johnson to Acquire V-Wave for Up to $1.7 Billion

October 9, 2024

Healthcare Services

Johnson & Johnson (J&J) entered into a definitive agreement to acquire V-Wave, a privately held heart-failure treatment company, for an upfront payment of $600 million and potential regulatory/commercial milestone payments up to about $1.1 billion (total up to ~$1.7 billion). The acquisition is expected to close before the end of 2024, and will add V-Wave’s Ventura Interatrial Shunt implant technology to the J&J MedTech Cardiovascular portfolio.

Boston Scientific Acquires Axonics, Inc.

November 15, 2024

Medical Devices

Boston Scientific agreed to acquire Axonics, a medical technology company focused on urinary and bowel dysfunction, for $71 per share in cash, valuing the equity at approximately $3.7 billion. The boards approved the transaction, which was expected to close in the first half of 2024, and Boston Scientific later announced the acquisition closed on November 15, 2024.